Similar articles

• Reply: To PMID 24798001.

  Haq F, Ahn SM. Haq F, et al. Hepatology. 2015 Oct;62(4):1324-5. doi: 10.1002/hep.27740. Epub 2015 Apr 8. Hepatology. 2015. PMID: 25677638 No abstract available.
• New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment.

  Vilarinho S, Calvisi DF. Vilarinho S, et al. Hepatology. 2014 Dec;60(6):1812-4. doi: 10.1002/hep.27311. Epub 2014 Oct 24. Hepatology. 2014. PMID: 25042754 No abstract available.
• Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.

  Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, Baek D, Haq F, Ansari AA, Lee SY, Chun SM, Choi S, Choi HJ, Kim J, Kim S, Hwang S, Lee YJ, Lee JE, Jung WR, Jang HY, Yang E, Sung WK, Lee NP, Mao M, Lee C, Zucman-Rossi J, Yu E, Lee HC, Kong G. Ahn SM, et al. Hepatology. 2014 Dec;60(6):1972-82. doi: 10.1002/hep.27198. Epub 2014 Sep 22. Hepatology. 2014. PMID: 24798001
• Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.

  Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, Hu B, Braddock M, Chen YP, Zheng MH. Liu WY, et al. Expert Opin Ther Targets. 2015 May;19(5):675-85. doi: 10.1517/14728222.2014.997711. Epub 2014 Dec 30. Expert Opin Ther Targets. 2015. PMID: 25547779 Review.
• The Spectrum of E2F in Liver Disease--Mediated Regulation in Biology and Cancer.

  Huntington JT, Tang X, Kent LN, Schmidt CR, Leone G. Huntington JT, et al. J Cell Physiol. 2016 Jul;231(7):1438-49. doi: 10.1002/jcp.25242. Epub 2016 Feb 2. J Cell Physiol. 2016. PMID: 26566968 Review.